Prestige sumer Healthcare (PBH) - 2026 Q3 - Earnings Call Transcript

Financial Data and Key Metrics Changes - Q3 revenue was $283 million, a decline of 2.4% from $290.3 million in the prior year, primarily due to lower eye and ear care category sales attributed to Clear Eyes supply constraints [10][12] - Adjusted EPS was $1.14, down slightly from $1.22 in the prior year, reflecting lower sales and increased G&A costs [10][15] - Free cash flow for the year to date was $209 million, up 13% compared to the previous year [5][10] Business Line Data and Key Metrics Changes - Sales declines were largely due to anticipated impacts from Clear Eyes supply chain constraints, with North America segment revenues decreasing 4.4% and international segment revenues down 90 basis points [12][13] - E-commerce channels showed strong growth, offsetting declines in other categories like analgesics and cough and colds [12][19] Market Data and Key Metrics Changes - The company continues to see positive consumption trends in e-commerce, with consumption growth over 10% in Q3 [34] - The eye care category is expected to see sequential improvements in supply, driven by strategic actions taken, including the acquisition of Pillar Five [6][8] Company Strategy and Development Direction - The company is focused on a disciplined capital allocation strategy, enhancing shareholder value through stock repurchases and strategic acquisitions [5][17] - The acquisition of Pillar Five is expected to improve supply chain control and production capabilities for eye care products [7][8] Management's Comments on Operating Environment and Future Outlook - Management noted heightened business environment uncertainty due to supply chain constraints, high inflation, and geopolitical events [3] - The company has narrowed its sales outlook for fiscal 2026 to approximately $1.1 billion, reflecting consumption momentum in growth channels but offset by slower order patterns in others [19] Other Important Information - The company anticipates a full-year G&A of just over 10% as a percentage of sales, with adjusted diluted EPS expected to be approximately $4.54 for the year [15][19] - The company has repurchased over $150 million in shares year to date, nearly 5% of shares outstanding [17] Q&A Session Summary Question: Are you seeing consumption shift to other retailers? - Management confirmed a continuation of channel shifts, with consumption picking up based on where consumers purchase products [22][24] Question: When might the headwinds go away? - Management indicated it is difficult to predict, but they are well-positioned to manage through the volatility [25] Question: Update on eye care supply and margins? - Management expects sequential improvement in Clear Eyes supply, with stable margins anticipated as the business normalizes [30][32] Question: E-commerce growth and penetration? - E-commerce consumption grew over 10% in Q3, with management noting the importance of aligning marketing initiatives with consumer shopping behavior [34][35] Question: Update on women's health business? - Monistat is performing well, while Summer's Eve is positioned for long-term growth despite some volatility [36][37] Question: Capital allocation and stock buybacks? - Management emphasized the importance of investing in brands while also evaluating M&A opportunities, with stock buybacks being a secondary focus [42][44] Question: Sales outlook for Q4? - Management indicated that the sales guidance reflects order patterns seen in Q3, with consumption remaining strong [47][48] Question: Expectations for fiscal 2027? - Management expressed confidence in base business performance and anticipated improvements in supply conditions for Clear Eyes [52][53]